Posted inBiotechnology
Editor’s Corner: Fierce Biotech’s 10 most-read stories of 2024
For the end of this year, Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024’s reporting.…
Posted inBiotechnology
Ring Therapeutics lays off just under half of staff in 2nd wave of cuts this year, CEO set to step down
Ring Therapeutics, a Flagship Pioneering-backed biotech developing new viral vectors for gene therapy delivery, has cut its staff by just…
Posted inBiotechnology
Novartis, BioAge take on age-related diseases in $550M pact
Freshly public BioAge Labs has secured a multi-year partnership with Novartis that focuses on age-related diseases and includes the possibility…
Posted inBiotechnology
Fibrosis-focused Tvardi to go public via merger with cash-strapped Cara
Pruritus drug developer Cara Therapeutics kicked off the year halving its headcount, and the biotech has now found a new…
Posted inBiotechnology
Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh’s preclinical drug
Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for…
Posted inBiotechnology
Aurion’s regenerative eye disease med improves vision in phase 1/2 trial
The highest dose of Aurion Biotech’s cell therapy, the main component of which recently received approval in Japan, has improved…
Posted inBiotechnology
Cognition’s phase 2 SHIMMER results finally allow dementia drug to shine
The failure of Cognition Therapeutics’ Alzheimer’s disease candidate CT1812 in the SHINE trial earlier this year may have rubbed off…
Posted inBiotechnology
Novo Nordisk taps Photys for $186M cardiometabolic collab
With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a concerted…
Posted inBiotechnology
Novo Holdings leads SiteOne’s $100M series C for non-opioid pain treatments
SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target the peripheral…
Posted inBiotechnology
Sanofi, Teva look to ‘next frontier’ in IBD treatment after TL1A antibody hits mark in midstage trial
As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and Teva…